JP2024518776A5 - - Google Patents

Info

Publication number
JP2024518776A5
JP2024518776A5 JP2023565453A JP2023565453A JP2024518776A5 JP 2024518776 A5 JP2024518776 A5 JP 2024518776A5 JP 2023565453 A JP2023565453 A JP 2023565453A JP 2023565453 A JP2023565453 A JP 2023565453A JP 2024518776 A5 JP2024518776 A5 JP 2024518776A5
Authority
JP
Japan
Prior art keywords
seq
acid sequence
amino acid
chain variable
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023565453A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518776A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/026161 external-priority patent/WO2022232035A1/en
Publication of JP2024518776A publication Critical patent/JP2024518776A/ja
Publication of JP2024518776A5 publication Critical patent/JP2024518776A5/ja
Pending legal-status Critical Current

Links

JP2023565453A 2021-04-26 2022-04-25 抗adgre2抗体及びその使用 Pending JP2024518776A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163179756P 2021-04-26 2021-04-26
US63/179,756 2021-04-26
PCT/US2022/026161 WO2022232035A1 (en) 2021-04-26 2022-04-25 Anti-adgre2 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2024518776A JP2024518776A (ja) 2024-05-02
JP2024518776A5 true JP2024518776A5 (cg-RX-API-DMAC7.html) 2025-05-07

Family

ID=81648880

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565453A Pending JP2024518776A (ja) 2021-04-26 2022-04-25 抗adgre2抗体及びその使用

Country Status (17)

Country Link
US (1) US12540178B2 (cg-RX-API-DMAC7.html)
EP (1) EP4330283A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024518776A (cg-RX-API-DMAC7.html)
KR (1) KR20240004287A (cg-RX-API-DMAC7.html)
CN (1) CN117580860A (cg-RX-API-DMAC7.html)
AR (1) AR125450A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022266583A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023020371A2 (cg-RX-API-DMAC7.html)
CA (1) CA3214355A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003174A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023013195A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP23088752A (cg-RX-API-DMAC7.html)
IL (1) IL307940A (cg-RX-API-DMAC7.html)
MX (1) MX2023011712A (cg-RX-API-DMAC7.html)
PE (1) PE20242205A1 (cg-RX-API-DMAC7.html)
TW (1) TW202305003A (cg-RX-API-DMAC7.html)
WO (1) WO2022232035A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022266583A1 (en) 2021-04-26 2023-10-19 Millennium Pharmaceuticals, Inc. Anti-adgre2 antibodies and uses thereof
PE20241789A1 (es) 2021-04-26 2024-09-06 Millennium Pharm Inc Anticuerpos anti-clec12a y usos de los mismos
JP2024514974A (ja) 2021-04-26 2024-04-03 メモリアル スローン-ケタリング キャンサー センター Adgre2及び/またはclec12aを標的とするキメラ受容体及びその使用
CN120152735A (zh) * 2022-10-25 2025-06-13 武田药品工业株式会社 Adgre2嵌合受体nk细胞组合物和使用方法
EP4713363A1 (en) * 2023-05-15 2026-03-25 Syzygymed Inc Egf-like module containing mucin-like hormone-like 2 (erm2) binding agents and methods of use thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
US20250361317A1 (en) * 2024-05-24 2025-11-27 Janssen Biotech, Inc. Bispecific antibody targeting emr2 (cd312) and the t-cell receptor trbv19

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3681787D1 (de) 1985-07-05 1991-11-07 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
HK1008049A1 (en) 1987-09-11 1999-04-30 Whitehead Institute For Biomedical Research Transduced fibroblasts and use therefor
ATE110108T1 (de) 1987-12-11 1994-09-15 Whitehead Biomedical Inst Genetische modifizierung von endothelialen zellen.
DE68927996T2 (de) 1988-02-05 1997-12-04 Hughes Howard Med Inst Modifizierte hepatozyten und deren anwendung
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DE69123981T3 (de) 1990-10-31 2006-06-14 Cell Genesys Inc Nützliche retrovirale vektoren für die gentherapie
JPH07503124A (ja) 1991-06-14 1995-04-06 ゾーマ・コーポレーション 微生物によって生産される抗体断片とそれらの複合体
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5773019A (en) 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US6146361A (en) 1996-09-26 2000-11-14 Becton Dickinson And Company Medication delivery pen having a 31 gauge needle
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
WO1998047531A2 (en) 1997-04-21 1998-10-29 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
US6192891B1 (en) 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
US6277099B1 (en) 1999-08-06 2001-08-21 Becton, Dickinson And Company Medication delivery pen
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
ATE547080T1 (de) 2000-08-30 2012-03-15 Univ Johns Hopkins Vorrichtungen zur intraokularen arzneimittelabgabe
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
JP4383168B2 (ja) 2001-09-12 2009-12-16 ベクトン・ディキンソン・アンド・カンパニー マイクロ針投与デバイスおよび薬物投与デバイス
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US20040102469A1 (en) 2002-09-13 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for reducing the mortality rate
GB0222023D0 (en) 2002-09-21 2002-10-30 Aventis Pharma Ltd Inhaler
FR2849436B1 (fr) 2002-12-27 2007-01-05 Patrick Frayssinet Particules et ceramiques de phosphates de calcium pour transfection in vivo et in vitro
WO2004073551A2 (en) 2003-02-18 2004-09-02 Massachusetts Eye And Ear Infirmary Transscleral drug delivery device and related methods
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
CA2693771A1 (en) 2007-07-13 2009-01-22 Abbott Biotechnology Ltd. Methods and compositions for pulmonary administration of a tnf.alpha. inhibitor
NZ602220A (en) 2010-03-11 2014-10-31 Rinat Neuroscience Corp Antibodies with ph dependent antigen binding
EP2622074B1 (en) 2010-09-30 2014-11-12 Board Of Trustees Of Northern Illinois University Library-based methods and compositions for introducing molecular switch functionality into protein affinity reagents
CA2816763A1 (en) * 2010-11-05 2012-05-10 Transbio Ltd Markers of endothelial progenitor cells and uses thereof
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
AU2016355206A1 (en) * 2015-11-19 2018-05-24 Abbvie Stemcentrx Llc Novel anti-EMR2 antibodies and methods of use
EP3344263A4 (en) 2016-08-04 2020-07-01 Memorial Sloan-Kettering Cancer Center CANCER ANTIGEN TARGETS AND USES THEREOF
SG11202010763VA (en) 2018-05-03 2020-11-27 Univ Texas Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade
AU2022266583A1 (en) 2021-04-26 2023-10-19 Millennium Pharmaceuticals, Inc. Anti-adgre2 antibodies and uses thereof
PE20241789A1 (es) 2021-04-26 2024-09-06 Millennium Pharm Inc Anticuerpos anti-clec12a y usos de los mismos
JP2024514974A (ja) 2021-04-26 2024-04-03 メモリアル スローン-ケタリング キャンサー センター Adgre2及び/またはclec12aを標的とするキメラ受容体及びその使用
CN114106199B (zh) 2021-11-19 2022-07-12 广州百暨基因科技有限公司 靶向adgre2的嵌合抗原受体及其应用
CN120152735A (zh) 2022-10-25 2025-06-13 武田药品工业株式会社 Adgre2嵌合受体nk细胞组合物和使用方法

Similar Documents

Publication Publication Date Title
JP2023540526A5 (cg-RX-API-DMAC7.html)
CN112969476B (zh) 多特异性蛋白分子
JP2022512132A5 (cg-RX-API-DMAC7.html)
JP2021534762A5 (cg-RX-API-DMAC7.html)
JP2020510422A5 (cg-RX-API-DMAC7.html)
JP2024516645A5 (cg-RX-API-DMAC7.html)
JP2020501598A5 (cg-RX-API-DMAC7.html)
JP2026041845A5 (cg-RX-API-DMAC7.html)
JP2015163068A5 (cg-RX-API-DMAC7.html)
JP2023525695A5 (cg-RX-API-DMAC7.html)
JP2023509373A5 (cg-RX-API-DMAC7.html)
JP2021530244A5 (cg-RX-API-DMAC7.html)
JP2023543493A5 (cg-RX-API-DMAC7.html)
IL280487B2 (en) Anti-mica/b antibodies that block mica/b shedding and methods of use
CN115461373A (zh) 密蛋白18.2的抗体及其用途
WO2023060277A1 (en) Composition of multispecific antibodies targeting cdh17-expressing tumors and method of making and using thereof
JP2022544825A5 (cg-RX-API-DMAC7.html)
JP2021512604A5 (cg-RX-API-DMAC7.html)
TW202248211A (zh) 針對ror1與cd3之多特異性抗體
JP2023511898A5 (cg-RX-API-DMAC7.html)
JP2023552852A5 (cg-RX-API-DMAC7.html)
JP2024512135A5 (cg-RX-API-DMAC7.html)
JP2024515560A5 (cg-RX-API-DMAC7.html)
JP2025503229A5 (cg-RX-API-DMAC7.html)
JP2024020436A5 (cg-RX-API-DMAC7.html)